Ablation

CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal

Retrieved on: 
Monday, January 11, 2021
Medical technology, Medicine, Equipment, Microport, Microport, Cardiac arrhythmia, Heartlight, Atrial fibrillation, Port, Ablation

MARLBOROUGH, Massachusetts, Jan. 11, 2021 /PRNewswire/ -- CardioFocus, Inc ., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.

Key Points: 
  • MARLBOROUGH, Massachusetts, Jan. 11, 2021 /PRNewswire/ -- CardioFocus, Inc ., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.
  • "Based on the success in France, we believe MicroPort will achieve rapid HeartLight X3 adoption in both Spain and Portugal."
  • "We are convinced our collaboration in Europe with CardioFocus is a win-win partnership," said Philippe Wanstok, SVP Global Sales and Marketing at MicroPort CRM.
  • "The HeartLight X3 ablation system is the perfect complement to our MicroPort EP range of catheters and Columbus 3D imaging system.

Monteris Medical Announces Health Care Service Corporation Policy Coverage for its NeuroBlate® System Laser Interstitial Thermotherapy for Brain Tumors and Epilepsy

Retrieved on: 
Wednesday, January 6, 2021
Medicine, Clinical medicine, Medical specialties, Radiology, Ablation, Brain tumor, Neurosurgery, Magnetic resonance imaging, Interventional radiology, Ablative brain surgery, Interventional oncology

This update follows a similar policy decision by Blue Cross Blue Shield of North Carolina, which also provides coverage of MRI-guided laser ablation for patients with brain tumors and epilepsy.

Key Points: 
  • This update follows a similar policy decision by Blue Cross Blue Shield of North Carolina, which also provides coverage of MRI-guided laser ablation for patients with brain tumors and epilepsy.
  • Many patients with brain tumors face situations in which traditional open brain surgery is neither possible, nor the preferred approach.
  • Monteris Medical's NeuroBlate laser ablation system is a tool used to destroy targeted tissue in the brain and provides a minimally invasive alternative for these patients and their physicians.
  • The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy.

Avenda Health Receives FDA Clearance for their Focal Laser Ablation System

Retrieved on: 
Wednesday, December 16, 2020
Plasma physics, Laser medicine, Medicine, Ablation, Laser ablation, Academic disciplines, Physical sciences

SANTA MONICA, Calif., Dec. 16, 2020 /PRNewswire/ --Avenda Health, a software and medical device company that spun out of UCLA, announced today that the Food and Drug Administration (FDA) has cleared their focal laser ablation system.

Key Points: 
  • SANTA MONICA, Calif., Dec. 16, 2020 /PRNewswire/ --Avenda Health, a software and medical device company that spun out of UCLA, announced today that the Food and Drug Administration (FDA) has cleared their focal laser ablation system.
  • Avenda Health Receives FDA Clearance for their Office-Based Focal Laser Ablation System.
  • Avenda Health's image-guided focal laser ablation system is designed to ablate soft tissue in a physician's office.
  • They have developed a focal laser ablation system and continue to develop investigational AI cancer margin prediction software.

Acutus Medical Launches AcQBlate® Force Sensing Ablation System in Europe

Retrieved on: 
Monday, December 7, 2020
Medicine, Branches of biology, Cardiac electrophysiology, Clinical medicine, Interventional radiology, Biotronik, Radiofrequency ablation, Atrial fibrillation, Ablation, Heart

CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the launch of the AcQBlate Force Sensing Ablation System in Europe after securing CE Mark for the companys AcQBlate FORCE ablation catheter and the Qubic Force Sensing Module (Qubic Force).

Key Points: 
  • CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the launch of the AcQBlate Force Sensing Ablation System in Europe after securing CE Mark for the companys AcQBlate FORCE ablation catheter and the Qubic Force Sensing Module (Qubic Force).
  • The AcQBlate Force Sensing Ablation System, which incorporates the first and only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market (AcQBlate Force), also integrates two state-of-the-art components made available through Acutus Medicals international alliance with BIOTRONIK:
    When combined with AcQMap, Acutus proven ultra-high resolution, 3D cardiac imaging and mapping system, the AcQBlate Force Sensing Ablation System represents a complete and highly differentiated solution for the electrophysiologic (EP) mapping and RF ablation of cardiac arrhythmias.
  • The Qubic RF generator and the Qiona irrigation pump, available through Acutus Medicals partnership with BIOTRONIK, complete the AcQBlate Force Sensing Ablation System.
  • The AcQBlate Force Sensing Ablation System may also operate in a standalone manner, enabling physicians the benefit of contact force sensing technology even in simple ablation cases where sophisticated 3D diagnostic mapping may not be required.

BRIC Gynecological Devices Market Outlook to 2025: Focus on Endometrial Ablation Devices and Female Sterilization Devices - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 2, 2020
Medical devices, Health, Sterilization, Endometrial ablation, Gynecological surgery, Ablation, Tubal ligation

2.1 What Is This Report About?

Key Points: 
  • 2.1 What Is This Report About?
  • 4.1.1 Endometrial Ablation Devices Market, Brazil, Revenue ($m), by Segment, 2015-2025
    4.1.2 Female Sterilization Devices Market, Brazil, Revenue ($m), by Segment, 2015-2025
    4.2.1 Endometrial Ablation Devices Market, Brazil, Volume (Units), by Segment, 2015-2025
    4.2.2 Female Sterilization Devices Market, Brazil, Volume (Units), by Segment, 2015-2025

Global Cardiac Ablation Market Forecast for 2020-2024 | COVID-19 Impact Analysis and Key Trends | Technavio

Retrieved on: 
Friday, November 20, 2020
Surgery, Health, Cardiology, Ablation

View the full release here: https://www.businesswire.com/news/home/20201119006073/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201119006073/en/
    Technavio has announced its latest market research report titled Global Cardiac Ablation Market 2020-2024 (Graphic: Business Wire)
    Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The report on the cardiac ablation market provides a holistic update with market size, forecasts of the trends, growth drivers, and challenges, as well as a detailed vendor analysis.
  • The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.
  • This study identifies transforming marketing and sales strategies for cardiac ablation as one of the prime reasons driving the cardiac ablation market growth during the next few years.

Global Cardiac Ablation Devices Market Analysis and Forecasts to 2024 with COVID-19 Impact Analysis

Retrieved on: 
Monday, November 16, 2020
Plasma physics, Ablation, Catheter ablation, Heart

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- The "Global Cardiac Ablation Devices Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 16, 2020 /PRNewswire/ -- The "Global Cardiac Ablation Devices Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • Though, the growth of global cardiac ablation devices market would be negatively impacted by various challenges.
  • This report provides in-depth analysis of the global cardiac ablation devices, with detailed analysis of market size and growth.
  • The report provides analysis of the cardiac ablation devices market by value, by volume, by application, by procedures & by region.

Kardium Performs First Cases with the Globe® Positioning System

Retrieved on: 
Thursday, November 12, 2020
Cardiology, Software, Medical Supplies, Surgery, Health, Medical devices, Technology, Other Health, Navigation, Navigation system, Ablation, Globe, Here Technologies, Software, Cartography, Articles

Kardium is pleased to announce the first clinical use of the Globe Positioning System (GPS) the new 3D mapping and navigation feature of its flagship product, the Globe Mapping and Ablation System.

Key Points: 
  • Kardium is pleased to announce the first clinical use of the Globe Positioning System (GPS) the new 3D mapping and navigation feature of its flagship product, the Globe Mapping and Ablation System.
  • View the full release here: https://www.businesswire.com/news/home/20201112005237/en/
    Prof. Hans Kottkamp performs the first clinical procedure with the Globe Positioning System, the new 3D mapping and navigation system for the Globe Mapping and Ablation System.
  • The Globe Mapping and Ablation System now provides EPs with the ultimate in high-definition mapping, added Kevin Chaplin, Kardium CEO.
  • Kardiums Globe Mapping and Ablation System, now with the Globe Positioning System mapping and navigation feature, is available for commercial sale in Europe.

Tumor Ablation Market Worth $ 1072.87 Million, Globally, by 2027 at 12.1% CAGR: Verified Market Research

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Medicine, Clinical medicine, Interventional radiology, Microwave ablation, Cryoablation, Ablation, Bone metastasis, Liver cancer, Radiofrequency ablation, Combinatorial ablation and immunotherapy

JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".

Key Points: 
  • JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".
  • According to Verified Market Research, the Global Tumor Ablation Market was valued at USD 458.30 Million in 2019 and is projected to reach USD 1072.87 Million by 2027, growing at a CAGR of 12.1% from 2020 to 2027.
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market.
  • Verified Market Research has segmented the Global Tumor Ablation Market on the basis of Technology, Mode of Treatment, Application and Geography.

Tumor Ablation Market Worth $ 1072.87 Million, Globally, by 2027 at 12.1% CAGR: Verified Market Research

Retrieved on: 
Thursday, November 5, 2020
Interventional radiology, Medicine, Clinical medicine, Medical specialties, Microwave ablation, Cryoablation, Ablation, Bone metastasis, Cancer, Radiofrequency ablation

Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market

Key Points: 
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market
    JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".
  • According to Verified Market Research, the Global Tumor Ablation Market was valued at USD 458.30 Million in 2019 and is projected to reach USD 1072.87 Million by 2027, growing at a CAGR of 12.1% from 2020 to 2027.
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market.
  • Verified Market Research has segmented the Global Tumor Ablation Market on the basis of Technology, Mode of Treatment, Application and Geography.